Pantoprazole

Pantoprazole

300px
Systematic (IUPAC) name
(RS)-6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzo[d]imidazole
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	US FDA: Pantoprazole
Pregnancy category	AU: B3 US: B (No risk in non-human studies)
Routes of administration	Oral and intravenous
Legal status
Legal status	℞ (Prescription only)
Pharmacokinetic data
Bioavailability	77%
Metabolism	Hepatic (CYP2C19 and 3A4)
Biological half-life	1 hour
Excretion	Renal
Identifiers
CAS Number	102625-70-7
ATC code	A02BC02 (WHO)
PubChem	CID 4679
DrugBank	APRD00073
ChemSpider	4517
Chemical data
Formula	C16H15F2N3O4S
Molar mass	383.371 g/mol[[]]
(verify)

Pantoprazole (sold under various brand names including Protium and Protonix) is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease. Initial treatment is generally of eight weeks' duration, after which another eight week course of treatment may be considered if necessary. It can be used as a maintenance therapy for long term use after initial response is obtained. This medication may affect the results of certain lab tests, such as drug screenings (pantoprazole can cause a false positive for THC, the psychoactive component of cannabis). The active ingredient in PROTONIX (pantoprazole sodium) Delayed-Release Tablets is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]-1 H -benzimidazole sesquihydrate, a compound that inhibits gastric acid secretion.

Pharmacology

Pantoprazole is metabolized in the liver by the cytochrome P450 system. Metabolism mainly consists of demethylation by CYP2C19 followed by sulfation. Another metabolic pathway is oxidation by CYP3A4. Pantoprazole metabolites are not thought to have any pharmacological significance. Pantoprazole is relatively free of drug interactions; however, it may alter the absorption of other medications that depend on the amount of acid in the stomach, such as ketoconazole or digoxin.

Availability

Pantoprazole was developed by Altana (owned by Nycomed) and was licensed in the USA to Wyeth (which was taken over by Pfizer) and is currently marketed under the brand name Protonix by Wyeth-Ayerst Laboratories,Pantec by Concept Pharmaceuticals, Somac by Pfizer, as API by Vanguard Therapeutics, Astropan by Astron Lifesciences, as Fenix by Bosnalijek, as Pantoloc or Somac by Nycomed, as Protium in the UK, as Inipomp by Sanofi-Aventis or Eupantol by Nycomed in France, as Pantozol by Nycomed in Germany, Pantodac in India, Zurcazol in Greece, as Protonex by Abdi İbrahim in Turkey , as Pantup in Ireland and as TopZole in South Africa.and Aciryl by schwartz in india. It is available by prescription in delayed-release tablets. It is also available for intravenous use.

On December 24, 2007, Teva Pharmaceutical released an AB-rated generic alternative to Protonix. . This was followed by generic equivalents from Sun Pharma and Kudco Pharma. Wyeth sued all three for patent infringement and launched its own generic version of Protonix with Nycomed.

External links

• Protonix (Pantoprazole Sodium) label
• PubDrug

da:Pantoprazol tr:Pantoprazol